Assess long term persistence of a primary dose of GSK Biologicals' meningococcal vaccine 134612 versus one dose of Mencevax ACWY in healthy adolescents/young adults (15 to 19 years at vaccination).
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 polysaccharide (Primary) ; Meningococcal vaccine groups A C W-135 polysaccharide
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 02 Feb 2010 Actual end date (May 2009) and actual number of patients (42) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2006 New trial record.